Colazal (Balsalazide Disodium) Patent Expiration, LOE Window & CMS Spending

Colazal (Balsalazide Disodium) by Bausch Health: FDA Orange Book LOE 2027-02-24, 5 AB generics, $175K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN020610 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-02-24
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$175K
2024 Medicare Part D Spend$175K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 17.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.